Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance-Reference-Cited by-同舟云学术

Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance

Published:2019-02 Issue:2 Volume:38 Page:184-192
ISSN:1044-5498
Container-title:DNA and Cell Biology
language:en
Short-container-title:DNA and Cell Biology

Author:

Rezaei Zohreh¹,Sebzari Ahmadreza²,Kordi-Tamandani Dor Mohammad¹,Dastjerdi Kazem²³

Affiliation:

1. Department of Biology, University of Sistan and Baluchestan, Zahedan, Iran.

2. Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.

3. Department of Medical Biotechnology, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.

Publisher

Mary Ann Liebert Inc

Subject

Cell Biology,Genetics,Molecular Biology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/dna.2018.4427

Reference52 articles.

1. Treatment of HER2-positive breast cancer: current status and future perspectives

2. c-Myb and Bcl-x Overexpression Predicts Poor Prognosis in Colorectal Cancer

3. miR-340 suppresses cell migration and invasion by targeting MYO10 in breast cancer

4. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool

5. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma microRNA-195, −34c, and − 1246 as novel biomarkers for the diagnosis of trastuzumab-resistant HER2-positive breast cancer patients;Toxicology and Applied Pharmacology;2023-09

2. Current Advancements and Future Perspectives of Immunotherapy in Breast Cancer Treatment;Immuno;2023-05-30

3. The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective;Cancers;2022-10-29

4. Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer;Computational and Mathematical Methods in Medicine;2022-09-17

5. Analysis of exosome-derived microRNAs as early biomarkers of lipopolysaccharide-induced acute kidney injury in rats;Frontiers in Physiology;2022-08-26